249 related articles for article (PubMed ID: 31888672)
1. Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine.
Tsimberidou AM; Hong DS; Wheler JJ; Falchook GS; Janku F; Naing A; Fu S; Piha-Paul S; Cartwright C; Broaddus RR; Nogueras Gonzalez GM; Hwu P; Kurzrock R
J Hematol Oncol; 2019 Dec; 12(1):145. PubMed ID: 31888672
[TBL] [Abstract][Full Text] [Related]
2. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
3. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
Stockley TL; Oza AM; Berman HK; Leighl NB; Knox JJ; Shepherd FA; Chen EX; Krzyzanowska MK; Dhani N; Joshua AM; Tsao MS; Serra S; Clarke B; Roehrl MH; Zhang T; Sukhai MA; Califaretti N; Trinkaus M; Shaw P; van der Kwast T; Wang L; Virtanen C; Kim RH; Razak AR; Hansen AR; Yu C; Pugh TJ; Kamel-Reid S; Siu LL; Bedard PL
Genome Med; 2016 Oct; 8(1):109. PubMed ID: 27782854
[TBL] [Abstract][Full Text] [Related]
4. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.
Tsimberidou AM; Iskander NG; Hong DS; Wheler JJ; Falchook GS; Fu S; Piha-Paul S; Naing A; Janku F; Luthra R; Ye Y; Wen S; Berry D; Kurzrock R
Clin Cancer Res; 2012 Nov; 18(22):6373-83. PubMed ID: 22966018
[TBL] [Abstract][Full Text] [Related]
5. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience.
Schwaederle M; Parker BA; Schwab RB; Daniels GA; Piccioni DE; Kesari S; Helsten TL; Bazhenova LA; Romero J; Fanta PT; Lippman SM; Kurzrock R
Mol Cancer Ther; 2016 Apr; 15(4):743-52. PubMed ID: 26873727
[TBL] [Abstract][Full Text] [Related]
6. Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies.
Kato S; Okamura R; Sicklick JK; Daniels GA; Hong DS; Goodman A; Weihe E; Lee S; Khalid N; Collier R; Mareboina M; Riviere P; Whitchurch TJ; Fanta PT; Lippman SM; Kurzrock R
Int J Cancer; 2020 Jun; 146(12):3450-3460. PubMed ID: 31782524
[TBL] [Abstract][Full Text] [Related]
7. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M
Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291
[TBL] [Abstract][Full Text] [Related]
8. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials.
Subbiah IM; Falchook GS; Kaseb AO; Hess KR; Tsimberidou AM; Fu S; Subbiah V; Hong DS; Naing A; Piha-Paul SA; Akmal O; Janku F; Kurzrock R
Oncotarget; 2015 Sep; 6(29):28453-62. PubMed ID: 26164085
[TBL] [Abstract][Full Text] [Related]
9. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses.
Tsimberidou AM; Wen S; Hong DS; Wheler JJ; Falchook GS; Fu S; Piha-Paul S; Naing A; Janku F; Aldape K; Ye Y; Kurzrock R; Berry D
Clin Cancer Res; 2014 Sep; 20(18):4827-36. PubMed ID: 24987059
[TBL] [Abstract][Full Text] [Related]
10. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.
Wheler JJ; Janku F; Naing A; Li Y; Stephen B; Zinner R; Subbiah V; Fu S; Karp D; Falchook GS; Tsimberidou AM; Piha-Paul S; Anderson R; Ke D; Miller V; Yelensky R; Lee JJ; Hong DS; Kurzrock R
Cancer Res; 2016 Jul; 76(13):3690-701. PubMed ID: 27197177
[TBL] [Abstract][Full Text] [Related]
11. Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine.
Tsimberidou AM
Curr Probl Cancer; 2017; 41(3):176-181. PubMed ID: 28410846
[TBL] [Abstract][Full Text] [Related]
12. Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach.
Kato S; Kurasaki K; Ikeda S; Kurzrock R
Oncologist; 2018 Feb; 23(2):171-178. PubMed ID: 29038235
[TBL] [Abstract][Full Text] [Related]
13. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
[TBL] [Abstract][Full Text] [Related]
14. The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value.
Jiang X; Pissaloux D; De La Fouchardiere C; Desseigne F; Wang Q; Attignon V; Fondrevelle ME; De La Fouchardiere A; Perol M; Cassier P; Seigne C; Perol D; Ray-Coquard I; Meeus P; Fayette J; Flechon A; Le Cesne A; Penel N; Tredan O; Blay JY
Oncotarget; 2015 Sep; 6(28):26388-99. PubMed ID: 26317543
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study.
Khoja L; Atenafu EG; Suciu S; Leyvraz S; Sato T; Marshall E; Keilholz U; Zimmer L; Patel SP; Piperno-Neumann S; Piulats J; Kivelä TT; Pfoehler C; Bhatia S; Huppert P; Van Iersel LBJ; De Vries IJM; Penel N; Vogl T; Cheng T; Fiorentini G; Mouriaux F; Tarhini A; Patel PM; Carvajal R; Joshua AM
Ann Oncol; 2019 Aug; 30(8):1370-1380. PubMed ID: 31150059
[TBL] [Abstract][Full Text] [Related]
16. Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study.
Sicklick JK; Kato S; Okamura R; Patel H; Nikanjam M; Fanta PT; Hahn ME; De P; Williams C; Guido J; Solomon BM; McKay RR; Krie A; Boles SG; Ross JS; Lee JJ; Leyland-Jones B; Lippman SM; Kurzrock R
Genome Med; 2021 Oct; 13(1):155. PubMed ID: 34607609
[TBL] [Abstract][Full Text] [Related]
17. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
Albin N; Mc Leer A; Sakhri L
Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
[TBL] [Abstract][Full Text] [Related]
18. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
19. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.
London WB; Bagatell R; Weigel BJ; Fox E; Guo D; Van Ryn C; Naranjo A; Park JR
Cancer; 2017 Dec; 123(24):4914-4923. PubMed ID: 28885700
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV
Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
